Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline resectable PC, offering improved resection rates and enabling early intervention and patient selection. Several retrospective studies have validated its efficacy. However, previous studies have lacked intention-to-treat analyses and appropriate resectability classifications. Randomized comparative trials may help to enhance the clinical applicability of evidence. Therefore, after searching the MEDLINE database, this scoping review presents a comprehensive summary of the evidence from published (n = 14) and ongoing (n = 12) randomized Phase II and III trials. Diverse regimens and their outcomes were explored for both resectable and borderline resectable PC. While some trials have supported the efficacy of NAT, others have demonstrated no clear survival benefits for patients with resectable PC. The utility of NAT has been confirmed in patients with borderline resectable PC, but the optimal regimens remain debatable. Ongoing trials are investigating novel regimens, including immunotherapy, thereby highlighting the dynamic landscape of PC treatment. Studies should focus on biomarker identification, which may enable precision in oncology. Future endeavors aim to refine treatment strategies, guided by precision oncology.
胰腺癌是一种致死性疾病，需要创新的治疗方法以提高生存率。新辅助治疗在可切除及临界可切除胰腺癌中受到关注，可提高切除率，实现早期干预和患者筛选。多项回顾性研究已证实其疗效。然而，既往研究缺乏意向性治疗分析和恰当的可切除性分类。随机对照试验可能有助于提升证据的临床适用性。为此，本研究通过检索MEDLINE数据库，对已发表（14项）和正在进行（12项）的II期及III期随机试验证据进行了系统性梳理。针对可切除与临界可切除胰腺癌，探讨了不同治疗方案及其疗效。部分试验支持新辅助治疗的疗效，而另一些研究显示其对可切除胰腺癌患者无明确生存获益。新辅助治疗在临界可切除胰腺癌患者中的价值已获证实，但最佳方案仍存争议。当前正在进行的试验正在探索包括免疫治疗在内的新型方案，凸显了胰腺癌治疗领域的动态发展。未来研究应聚焦生物标志物鉴定，以实现肿瘤精准治疗。在精准肿瘤学指导下，优化治疗策略是未来重要方向。
肿瘤(癌症)患者之家